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Abstract
Celiac disease (CD) is an intestinal inflammatory disease 
that manifests in genetically susceptible individuals 
when exposed to dietary gluten. It is a common chronic 
disorder, with a prevalence of 1% in Europe and North 
America. Although the disease primarily affects the gut, 
the clinical spectrum of CD is remarkably varied, and 
the disease can affect many extraintestinal organs and 
systems, including the liver. The hepatic dysfunction 
presenting in CD ranges from asymptomatic liver 
enzyme elevations or nonspecific reactive hepatitis 
(cryptogenic liver disorders), to chronic liver disease. 
In this article, we review the clinical presentations 
and possible mechanisms of CD-related liver injury to 
identify strategies for the diagnosis and treatment of 
these disorders in childhood.
Key words: Celiac disease; Cryptogenic hypertran-
saminasemia; Autoimmune liver disease; End-stage liver 
disease; Fatty liver
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Core tip: Celiac disease (CD) is increasingly reported 
in children who are symptomless or present atypical 
symptoms and signs. Liver abnormalities are common 
extraintestinal manifestations in patients with CD and 
range from mild hepatic injury to severe liver disease. 
Awareness of this may help clinicians to improve 
strategies for the diagnosis and treatment of these 
disorders in childhood.
Anania C, De Luca E, De Castro G, Chiesa C, Pacifico L. Liver 
involvement in pediatric celiac disease. World J Gastroenterol 
2015; 21(19): 5813-5822  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v21/i19/5813.htm  DOI: http://dx.doi.
org/10.3748/wjg.v21.i19.5813
INTRODUCTION
Celiac disease (CD) is a chronic intestinal inflammatory 
disease that manifests in genetically susceptible 
individuals when exposed to dietary gluten[1]. The 
prevalence of CD is high in the European and North 
American population (1%), reaching 10% to 15% 
in patients who have first-degree relatives with this 
disease[1,2]. Genetic predisposition plays an important 
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role in the development of CD. Ninety percent 
of affected individuals carry the HLA-DQ2 (e.g., 
DQA1*0501-DQB1*0201) haplotype, 5% the DQ8 
haplotype (e.g., DQA1*0301-DQB1*0302), and the 
remaining 5% carry at least one of the two DQ2 alleles 
(frequently the DQB1*0201)[1,3]. Ingestion of gluten is 
necessary for the disease to develop[4]. Immunogenic 
peptides, created by deamidation of food-derived gliadin 
peptides by small intestinal tissue transglutaminase, 
are presented by antigen-presenting cells, mostly 
dendritic cells bearing HLA-DQ2 and DQ8 molecules, to 
proinflammatory CD4+ T cells, activating them[4]. Upon 
activation, the T cell produces a variety of cytokines 
like interferon-gamma as part of a Th1 response 
which results in clonal expansion of activated T cells, 
stimulation of cytotoxic T cells and B cell recruitment 
with subsequent production of anti-gliadin (AGA) 
and anti-transglutaminase antibodies (tTGA)[4]. Thus, 
intolerance to gluten is responsible for an immune-
mediated damage of the intestinal mucosa, which 
resolves after a gluten-free diet (GFD)[4].
CD diagnosis still relies on serology and small 
intestinal biopsy. tTGA and anti-endomysial antibodies 
(EMA) of the immunoglobulin A (IgA) class have 
the highest diagnostic accuracy with a sensitivity of 
98% and a specificity ranging from 90% to 99%. 
Deamidated gliadin peptide antibodies (DGP) of IgG 
class are a valuable diagnostic tool for identifying CD in 
patients with IgA deficiency and in children aged less 
than 2 years. Small bowel biopsy remains in adults 
the diagnostic gold standard, whereas in children and 
adolescents, as recently recommended, CD diagnosis 
can be accepted without the need for duodenal biopsy 
in symptomatic cases showing tTGA at high titer (> 
10-times upper normal limit), backed up by EMA and 
HLA-DQ2 and/or positive DQ8[3].
Although CD primarily affects the gut, the clinical 
manifestations of the disease are remarkably wide, 
with many extraintestinal organs and systems, 
including the liver, affected[5,6]. Liver changes in patients 
with CD have been reported since 1977 by Hagander 
et al[7] who demonstrated that transaminases were 
often increased in untreated CD, normalizing upon 
a strict GFD. More recently, studies performed after 
CD was identified as an autoimmune disease, have 
underlined the strong relationship between CD and 
autoimmune liver disorders. In this article, we review 
the clinical presentations and possible mechanisms of 
CD-related liver injury in order to identify strategies 
for the diagnosis and treatment of these disorders in 
childhood.
CRYPTOGENIC LIVER DISORDER (CELIAC 
HEPATITIS)
An association between CD and cryptogenic liver 
damage was first reported in 1977 by Hagander 
et al[7] who found that 40% of adults with incipient 
CD had increased serum concentrations of trans-
aminases, which returned to normal upon GFD in 
the majority of patients. One year later, Lindberg et 
al[8] reported elevation of serum aminotransferases 
in about one-third of pediatric patients with CD. 
Approximately one decade later, a mild to moderate 
hypertransaminasemia was observed in about 60% 
of symptomatic Italian children aged less than 2 
years with newly diagnosed CD[9]. Prevalence studies 
have reported that transaminases are elevated in 
39% to 47% of celiac adults[10-12] and in 26% to 
57% of children at diagnosis of CD (Table 1)[9,13-15]. 
Frequently, elevation in transaminases is mild, and is 
not associated with hepatomegaly or splenomegaly. In 
those patients who had undergone liver biopsy[10,16-18], 
histological changes such as Kupffer cell hyperplasia, 
mononuclear cell infiltration, steatosis, and mild fibrosis 
have been reported. In most cases, transaminase 
values normalized upon a 1-year GFD. 
Conversely, CD is present in patients investigated 
because of chronic unexplained hypertransaminasemia. 
Volta et al[18] for the first time reported that adults 
with elevated concentrations of aminotransferases 
of unknown origin were affected by symptomless 
CD. Five of the 55 study patients with cryptogenic 
elevation of transaminases fulfilled the criteria for CD 
diagnosis. Other common causes of liver disease were 
excluded. Three of these patients showed histologically 
a picture of reactive hepatitis typical of CD patients 
with elevated transaminases. The importance of these 
findings has been confirmed by other investigators, 
who found a similar prevalence of CD in large patient 
populations with cryptogenic hypertransaminasemia[19]. 
Recently, Sainsbury et al[20] conducted a meta-
analysis to estimate the prevalence of CD in adults 
with cryptogenic hypertransaminasemia, as well as 
the prevalence of hypertransaminasemia in those with 
incipient CD. The combined proportion with positive 
celiac serology and biopsy-proven CD in unexplained 
hypertransaminasemia were 6% (95%CI: 3%-10%) 
and 4% (1%-7%), respectively. However, there was 
significant heterogeneity between studies (P < 0.001). 
This is about four times the risk of CD, in the general 
population (about 1%)[20]. The combined proportion 
with abnormal serum aminotransferases in incipient 
CD was 27% (13%-44%). A 12-mo GFD normalized 
serum transaminase values in 63%-90% of patients. 
Discordant results were reported by Korpimäki et 
al[21] in a large population-based study including celiac 
patients with minor or atypical symptoms, and with 
or without GFD, as well as subjects without CD. The 
authors estimated that only 11% of the untreated 
celiac patients had elevated transaminase values. 
This prevalence was about the same as was found in 
treated CD cases and controls without CD. Variation 
in the CD clinical presentation and severity, as well 
as definition of the upper normal limits for serum 
transaminases may account for such discrepancies. 
Table 1  Studies reporting the prevalence of cryptogenic hypertransaminasemia in children and adolescents with celiac disease
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Also in children, hypertransaminasemia may 
represent the only manifestation of CD. In 1986 
an 11-year-old girl with a chronic and unexplained 
elevated aminotransferases was reported. Liver 
histology evidenced slight inflammation of the 
portal tract[22]. CD was diagnosed on the basis 
of antireticulin antibodies and subsequently by 
intestinal biopsy. Seven years later six children with 
chronic hypertransaminasemia and histologic findings 
ranging from reactive hepatitis to moderately active 
chronic hepatitis, were reported[23]. They were 
asymptomatic and had jejunal histology consistent 
with CD diagnosis. In all subjects, transaminases 
normalized on a GFD. Resolution of hepatic histologic 
lesions occurred in two children, whereas amino-
transferases increased in three children upon a 
gluten challenge[23]. Finally, in a prospective study 
involving 425 children and adolescents with isolated 
hypertransaminasemia, Iorio et al[24] found 166 
patients with persistently (more than 6 mo) elevated 
transaminases of whom three (1.8%) were identified 
as having CD. Therefore, routine screening for CD 
is to be recommended in children with otherwise 
unexplained hypertransaminasemia.
AUTOIMMUNE LIVER DISORDERS 
ASSOCIATED WITH CELIAC DISEASE
Autoimmune liver disorders (AILD), including autoi-
mmune hepatitis (AIH), primary sclerosing cholangitis 
(PSC), and primary biliary cirrhosis (PBC) have been 
shown to be associated with CD[25-28].
AIH is a progressive inflammatory liver disorder 
and is more common among females. It is associated 
serologically with high levels of aminotransferases and 
IgG, the presence of autoantibodies, and histologically 
with interface hepatitis in the absence of known 
etiology[29]. Hepatitis at the portal-parenchymal 
interface (“interface hepatitis”) is typical. The picture 
is characterized by a lymphoplasmacytic infiltrate 
crossing the limiting plate and invading the liver 
parenchyma. Other associated lesions are hepatocyte 
swelling and pycnotic necrosis. Fibrosis is found in 
all forms of the disease except the mildest ones[30]. 
Two types of AIH can be recognized: type 1 AIH is 
associated with antinuclear antibodies and/or smooth 
muscle antibodies and affects adult patients much 
more commonly, while type 2 AIH, characterized by 
antibodies to liver-kidney microsome type 1, is usually 
Ref. Study design Study 
population 
with CD
Diagnosis of CD Number of patients 
with elevated 
transaminases
Effect of GFD Comment
Bonamico et al[9], 1986 Observational 65 untreated 
symptomatic 
children aged 
6-mo to 18 yr
Intestinal biopsy 37 (56.9%) had 
elevated (> 45 
U/L) ALT (3.1%) 
or AST (29.2%) or 
both (24.6%)
Only 5 cases had 
a follow-up for 
3-4 wk after GFD: 
normalization of 
transaminases was 
achieved in all
Excluded were Hepatitis A and B, 
but not other causes of liver disease 
Farre et al[13], 2002 Prospective 114 untreated 
symptomatic 
children aged 
9-mo to 17 yr
Serology (EMA 
IgA or IgG 
and tTGA IgA) 
and/or intestinal 
biopsy
37 (32.0%) had 
elevated1 ALT-
or- AST (14.9%) or 
both (14.9%)
35 of 37 had a follow-
up for 9-18 mo after 
GFD: normalization 
of transaminases was 
achieved in all
Arslan et al[14], 2005 Observational 27 untreated 
symptomatic 
children with 
a mean age of 
6 (SD 5) years 
Serology (EMA 
IgA and AGA 
IgA/IgG) and/or 
intestinal biopsy 
7 (25.9%) had 
elevated ALT (> 45 
U/L)
All patients had 
normalization of 
transaminases after 2-11 
mo of GFD
Di Biase et al[15], 2010 Prospective 350 untreated 
children with 
suspected CD 
aged 1 to 16 yr
Serology and 
intestinal biopsy 
according to 
the ESPGHAN 
criteria
140 (40.0%) had 
elevated AST (≥ 
38 U/L) and/or 
ALT (≥ 41 U/L); 
four with values 
> 5 times upper 
normal levels
Normalization of 
transaminases after 
6 mo of GFD was 
achieved in 133 (97.8%) 
of 136 children with 
transaminase values < 
5 times upper normal 
levels
The four children with 
transaminase values > 5 times 
upper normal levels as well as 
the 3 children with persistent 
elevated transaminases had 
further laboratory investigation 
and were found to be affected by 
autoimmune hepatitis
1Normal reference values for AST < 50 U/L from 1 to 6 years, < 38 U/L from 6 to 18 years; for ALT < 31 U/L from 1 to 18 years. CD: Celiac disease; 
GFD: Gluten-free diet; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; IgA: Immunoglobulin A; IgG: Immunoglobulin G; EMA: Anti-
endomysial antibodies; tTGA: Anti-tissue transglutaminase antibodies; AGA: Anti-gliadin antibodies; ESPGHAN: European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition.
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confined to childhood CD[18,31].
In the late 1970s, CD was occasionally reported 
in patients with AIH[18,32-34]. Then several studies 
established a relationship between CD and AIH of both 
types 1 and 2[26]. The first of these studies included the 
largest cohort of AIH patients (e.g., 181, of whom 157 
with type 1 and 24 with type 2) who were screened 
for CD by serology[18]. Among these patients, eight 
[4.4% (3.8% with type 1 and 8.3% with type 2 AIH)] 
were found to have raised levels of EMA IgA. Of these 
8 antibody-positive patients, five underwent jejunal 
biopsy which revealed a subtotal villous atrophy typical 
of CD. In a recent systematic review[26] performed in 
adults, the prevalence of CD in AIH ranged between 2% 
and 20% but was approximately 4% in most studies. 
In children, at first the association between CD 
and AIH was only reported in isolated cases[35-37]. 
Subsequently pediatric surveys have reported a wide 
prevalence of CD in AIH ranging from 3.6% to 12% 
(Table 2)[38-43]. In an Italian retrospective (1990-2005) 
multicenter study, Caprai et al[39] found that among 
140 children with AILD, 23 (16%) had CD [19 with AIH 
(12 with type 1; 4 with type 2; 3 seronegative), 2 with 
autoimmune cholangitis and 2 with overlap syndrome]. 
CD was diagnosed before liver disease in 18 of them, 
though raised aminotransferases were found in 16 
at CD diagnosis. Conversely, five of the 23 patients 
had a diagnosis of AILD before the identification of 
CD. Nineteen patients had liver-related non-organ-
specific autoantibodies. Hepatic biopsy showed 
inflammatory lesions with features of autoimmune 
damage and different degrees of fibrosis in all 19 
subjects and cirrhosis in 4 of them. All patients on GFD 
achieved remission on immunosuppressive therapy, 
but 14 relapsed either because treatment ceased 
or because the GFD was not respected. Diamanti et 
al[40] retrospectively (1990-2006) evaluated the CD 
prevalence in 40 AIH children. There were five cases of 
CD in the 40 AIH patients (12.5%); all five CD patients 
had type 1 AIH. In four patients (80%), AIH preceded 
the diagnosis of CD. On GFD the level of transaminases 
mildly decreased, and never reached normal 
concentrations. Tosun et al[41] who retrospectively 
evaluated the presence of CD in 15 AIH patients, found 
a prevalence of 46% (95%CI: 21%-67%), being the 
highest ever reported in pediatric literature, although 
the sample size is small. In a prospective study 
involving 26 Egyptian patients (aged 3.5-21 years) 
with AIH, El-Shabrawi et al[42] reported an 11.5% 
prevalence of CD. Very recently, in a retrospective and 
prospective evaluation (1995-2000), Nastasio et al[43] 
reported that among 79 patients with AIH, CD was 
present in 15 (19%) of them (9 had type 1, 3 type 2, 
and 3 were seronegative). All these patients achieved 
sustained remission on a GFD when treated with 
immunosuppressive therapy.
There are two studies providing prospective data 
on AIH in children with CD (Table 3)[15,44]. Di Biase et 
al[15] showed that isolated hypertransaminasemia was 
present in 40% of CD subjects on a gluten-containing 
diet, and that 2% had AIH, while there were no other 
AILD. Liver tests became normal after GFD only in CD 
patients with isolated hypertransaminasemia, but not in 
AIH cases who required GFD plus immunosuppressant 
therapy. Ventura et al[44] showed that AILD were more 
frequent in adolescents and young adults with CD than 
in the general population. In particular, out of 374 CD 
patients 10 (1.1%) had a diagnosis of AIH. They also 
Ref. Study design Study population 
with AILD
Number of patients with CD Effect of GFD
Caprai et al[39], 2008 Retrospective 140 patients 
aged 7-125 mo 
with AILD
23 (16.4%) (19 with AIH; 2 with AIC; and 2 
with overlap syndrome) had CD on the basis of 
serology (EMA IgA and/or tTGA IgA)
Diagnosis of CD preceded the diagnosis of liver 
disease in 18 of the 23 patients
All patients achieved remission on GFD 
and immunosuppressive therapy, but 14 
relapsed because of discontinuation of 
therapy or during spontaneous gluten 
challenge
Diamanti et al[40], 2008 Retrospective 40 patients aged 
3-13.2 yr with 
AIH
5 (12.5%) had CD on the basis of serology and 
histological findings
In four patients CD was diagnosed after AIH 
onset
On GFD four patients showed a mild 
decrease in transaminases, but never a 
complete normalization
Tosun et al[41], 2010 Retrospective 15 patients aged 
4-15 yr with AIH
7 (46.0%) had CD on the basis of serology and 
histological findings
CD and AIH were diagnosed concomitantly
Not available
El-Shabrawi et al[42], 2011 Prospective 26 patients aged 
3.5-21 yr with 
AIH
CD serology (tTGA IgA and/or EMA IgA) was 
positive in 4 (15.4%). Three out of these four AIH 
(11.5%) showed histological findings of CD
Not available
Nastasio et al[43], 2013 Retrospective 
and Prospective
79 children and 
adolescents with 
AIH 
15 (19.0%) had CD on the basis of serology and 
histological findings
Diagnosis of CD preceded the diagnosis of liver 
disease in 8 of the 15 patients
All 15 patients on GFD achieved 
sustained remission when treated with 
immunosuppressive therapy
AILD: Autoimmune liver diseases; CD: Celiac disease; GFD: Gluten-free diet; AIH: Autoimmune hepatitis; EMA: Anti-endomysial antibodies; tTGA: Anti-
tissue transglutaminase antibodies.
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reported that in patients with CD, AILD rates increased 
as age at diagnosis increased, suggesting a possible 
relationship with duration of exposure to gluten[44]. 
 PSC is a cholestatic disorder characterized 
by inflammation and periductal fibrosis of the 
intrahepatic and/or extrahepatic bile ducts[45-47]. No 
characteristic autoantibody has been identified in PSC 
patients. The diagnosis depends on evidencing the 
characteristic biliary lesions in biopsy tissue or the 
intra and extrahepatic biliary tree abnormalities by 
cholangiography[47]. Many patients, especially children, 
have PSC-AIH overlap with features of both diseases, 
and this is termed autoimmune sclerosing cholangitis 
(ASC)[46,48]. ASC refers to cases with PSC who have 
positive autoantibodies and may have histological 
features overlapping with those seen in AIH[47]. In 
adults, PBC may also be found. This additional form 
of AILD is characterized by the presence of anti-
mitochondrial antibodies. It progresses slowly and 
is more common in females. Histologically, PBC is 
characterized by portal inflammation and immune-
mediated destruction of the intrahepatic bile ducts. 
Autoimmune cholangitis (AIC) is a cholestatic liver 
disorder with biochemical signs of cholestasis, 
histological features of inflammatory bile duct damage, 
and negativity for anti-mitochondrial antibodies. PSC, 
PBC, and AIC have been mainly described in adults 
with CD[21,49-53]. In children, the association between 
CD and PSC or AIH/ASC overlap syndrome or AIC has 
been only reported in two studies[39,54].
NONALCOHOLIC fATTY LIVER DISEASE/
NONALCOHOLIC STEATOHEPATITIS
Nonalcoholic fatty liver disease (NAFLD) is a spectrum 
of liver conditions ranging from simple, uncomplicated 
steatosis, to nonalcoholic steatohepatitis (NASH), 
with inflammation and liver cell injury progressive to 
cryptogenic cirrhosis. NAFLD has become the most 
common cause of chronic liver disease in children 
and adolescents. Case reports and cross-sectional 
studies describe the association of various forms of 
fatty liver with CD[55-60]. Wigg et al[55] found that 3 of 
22 adult patients with NASH had positive AGA IgA and 
IgG, and one of them had a histological diagnosis of 
CD. Grieco et al[56] reported histologically-diagnosed 
CD in 4 (13.3%) of 30 patients with laboratory 
diagnosis of NASH. After one year on GFD, the 
transaminase levels were normalized, and duodenal 
histology was improved. Nehra et al[57] investigating 
the relationship between NASH and CD, found that 
only one (2.1%) of the 47 study obese patients 
with NASH was positive for EMA IgA. In a study of 
59 overweight patients undergoing liver biopsy for 
persistent hypertransaminasemia, NASH was detected 
in 38 (64%) whereas simple steatosis was found in 
21 (36%)[58]. Six (10%) of the 59 patients showed 
positivity for tTGA and two (3.4%) of them also 
positivity for EMA IgA. Histology confirmed CD in the 
two patients positive for both markers. In both cases, 
liver enzymes went back to normal after a 6-mo 
GFD. In a study involving 121 patients with biopsy-
proven NAFLD, Lo Iacono et al[59] reported that the 
prevalence of histologically-confirmed CD was 3.3%. 
In an Iranian population of 116 patients with NAFLD 
(as diagnosed on the basis of elevated transaminase 
levels, liver ultrasound and/or liver biopsy), Rahimi et 
al[60] found the prevalence of histologically-confirmed 
CD to be 2.2%. Interestingly, CD was more commonly 
diagnosed among NAFLD patients having body mass 
index (BMI) < 27 kg/m² compared to those with BMI 
> 27 kg/m² (5.83% vs 0%, P = 0.001). Very recently, 
in a nationwide study of more than 26000 children and 
adults with CD, Reilly et al[61] found an increased risk 
of NAFLD compared to the general population. Excess 
risks were highest in the first year after CD diagnosis, 
but persisted through 15 years beyond diagnosis with 
CD.
On the basis of the above findings, we conclude 
that there is an association between CD and fatty liver. 
However, since fatty liver is not an unusual finding 
in the general population of developed countries, 
the association of hepatic steatosis with CD may be 
a coincidental finding rather than a true association. 
Ref. Study design Study population with CD Diagnosis of CD Number of patients 
with AIH
Effect of GFD
Ventura et al[44], 1999 Prospective 909 children and 
adolescents with CD (group 
1, < 2 yr of age; group 2, 2-10 
yr; group 3, > 10 yr)
Serology and intestinal 
biopsy according to 
the ESPGHAN criteria
10 (1.1%) had AIH, 
of whom 2.9% in 
group 2 and 0.8% in 
group 3
Not available
Di Biase et al[15], 2010 Prospective 350 untreated children with 
suspected CD aged 1 to 16 
yr
Serology and intestinal 
biopsy according to 
the ESPGHAN criteria
7 (2.0%) had AIH, of 
whom 5 type Ⅰ AIH
During treatment with GFD, steroids 
and azathioprine for 5 yr, all AIH 
persistently normalized clinical 
and biochemical parameters. After 
withdrawal, 6 patients maintained a 
sustained remission (12-63 mo)
CD: Celiac disease; AIH: Autoimmune hepatitis; GFD: Gluten-free diet; ESPGHAN: European Society for Paediatric Gastroenterology, Hepatology and 
Nutrition.
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To complicate matters further, fatty infiltration of 
the liver may be secondary to rapid weight loss or 
malabsorption, both etiologically linked to fatty liver. 
Future investigations should be undertaken to resolve 
this issue and should include pediatric populations for 
whom there are very few data at present.
SEVERE LIVER DAMAGE
Although rarely, severe liver disease has been 
described in adults with CD[62-64]. In a Finnish study, 
4 patients with severe liver failure awaiting liver 
transplantation were discovered to have CD (one 
had congenital liver fibrosis; one, a massive hepatic 
steatosis; and two patients had progressive hepatitis 
with no apparent cause)[62]. Their liver disease 
improved after GFD. The Authors then screened 185 
patients undergoing liver transplantation and found 
that 8 (4.3%) of them had CD, which is 4-10 times the 
population prevalence of CD in Finland. Most of these 
patients had AILD. Only 1 patient was on GFD. This 
suggests that in some cases of CD, GFD help to avoid 
end-stage liver disease. Subsequently, in a study from 
United States involving an ample cohort of individuals 
with end-stage AILD (n = 310) and non-AILD (n = 
178) who underwent liver transplantation[64], the 
prevalence of tTGA and EMA was significantly greater 
in HLA-DQ2- or HLA-DQ8-positive patients with end-
stage AILD compared with those with end-stage non-
AILD (14.2% vs 5.4%, P = 0.0001 and 4.3% vs 0.78%, 
P = 0.01, respectively), while the co-occurrence of tTGA 
and EMA was increased five-fold in end-stage AILD 
(3% vs 0.6%). However, the study was retrospective, 
and apart from two patients, intestinal tissues were not 
available for re-review. Thus, a definite diagnosis of CD 
was not possible for most of the patients positive for 
CD-related autoantibodies. When serum samples were 
tested 6-12 or ≥ 24 mo post-transplantation, tTGA and 
EMA became normal in 94% and 100% of patients, 
respectively. This occurred without excluding gluten 
from the diet which implies no relationship between 
gluten and autoantibody kinetics. The suppression of 
tTGA and EMA after the transplant suggests that the 
lack of autoantibody positivity of post-transplant sera 
cannot exclude a diagnosis of CD, therefore supporting 
the pre-transplantation screening of patients with end-
stage AILD[64].
In children, severe liver disease has been described 
in association with CD[65-68]. Demir et al[65] reported 
five celiac children with cryptogenic cirrhosis. In 
three patients with chronic diarrhea and hepatosple-
nomegaly, the diagnoses of CD and cirrhosis were 
concomitant, whereas in two patients, CD was 
diagnosed following that of cirrhosis. One to five years 
later, three patients on strict GDF had normal values of 
serum aminotransferases, and clinical improvement. 
The other two patients with poor dietary compliance 
had no improvement in liver function. Al-Hussaini et 
al[66] reported an 11-year-old girl with liver failure due 
to sclerosing cholangitis associated with CD. Treatment 
with ursodeoxycholic acid and GFD, and steroid tapered 
over three months, normalized the liver function 
tests. A few cases of CD with severe liver involvement 
requiring liver transplant have been also reported[67,68]. 
In a case-report, Pavone et al[67] described a 14-year-
old girl with CD and mild gastrointestinal symptoms 
developing, after a long exposure to gluten, severe 
hepatic dysfunction requiring liver transplantation. 
Casswall et al[68] reported six 13- to 36-mo-old girls 
who within 1-24 mo of the diagnosis of CD developed 
severe liver damage. Four of these girls had acute liver 
failure and two needed a liver transplant.
PATHOGENESIS Of LIVER DYSfUNCTION 
IN CD
The pathogenesis of the hypertransaminasemia 
and liver damage in CD remains poorly understood. 
Probably they involve increased intestinal permeability 
and alterations in gut microbiota, chronic intestinal 
inflammation, and genetic predisposition (Figure 1).
Since the liver receives three quarters of its blood 
supply from the intestine, it is one of the organs most 
exposed to gut-derived toxic factors[69-72]. Cross-
talk between the gut and the liver is an intriguing 
hypothesis that may explain the hepatobiliary 
changes associated with many intestinal inflammatory 
diseases including CD. The suggestion that increased 
intestinal permeability and altered gut microbiota may 
contribute to the development of several diseases was 
made since 1890 (Llewellyn Jones: “Theory of auto-
intoxication from gut bacteria”)[72]. Gut epithelial cells 
are linked to one another with tight junctions (TJs), 
which play an essential role in maintaining the integrity 
of the intestinal barrier and in demarcating microbes 
in the gut from the host immune system. Zonulin, a 
human protein known to reversibly regulate intestinal 
permeability by modulating intercellular TJs[73], is 
augmented in autoimmune conditions associated with 
TJ dysfunction including CD[74].
Patients with CD and hypertransaminasemia 
have an important increase in intestinal permeability 
compared with those whose liver enzymes are 
normal[11]. The increased intestinal permeability may 
ease the entry of toxins, antigens, and inflammatory 
substances (cytokines and/or autoantibodies) to the 
portal circulation and these mediators may play a 
part in the pathogenesis of hepatic involvement in 
CD. Interestingly, increased intestinal permeability 
caused by disruption of intercellular TJs in the intestine 
as well as increased prevalence of small intestinal 
overgrowth has been reported in adult patients with 
NAFLD[75]. Moreover, it has been found that serum 
zonulin concentration is increased in children and 
adolescents with NAFLD and correlates with the 
severity of steatosis[76]. This may also explain hepatic 
fat deposition in CD. Autoantibodies directed against 
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tTG are present in the liver and other extraintestinal 
tissues in CD. This raises the possibility of a pathogenic 
role for the humoral-mediated immune responses in 
liver injury observed in CD. It has also been suggested 
that an aberrant T lymphocyte homing to the liver 
may contribute to trigger immune hepatic damage. As 
matter of fact, an increased number of lymphocytes 
expressing molecules of intestinal origin have been 
discovered in hepatic sinusoidal endothelial cells in 
individuals with liver abnormalities[77]. Moreover, liver-
primed T cells have been demonstrated to migrate 
into the intestine and into the gut-associated lymphoid 
tissue, suggesting an enterohepatic lymphocyte 
circulation[78]. The ability of T cells of homing both 
to the liver and the intestine may explain the link 
between CD and liver diseases.
Considerable progress has been made toward 
understanding the role of genetics in autoimmune 
liver damage. It is well known that CD and some 
autoimmune liver disorders share HLA class Ⅱ 
molecules and haplotypes. The main genetic marker of 
CD is HLA-DQ2, which is present in about 95% of CD 
patients. HLA-DQ2 is in strong linkage disequilibrium 
with HLA-DR3, which is the major HLA risk factor for 
AIH[79].
CONCLUSION
CD is increasingly reported in children who are 
symptomless or present atypical symptoms and 
signs. Liver abnormalities are common extraintestinal 
manifestations in patients with CD and range from 
mild hepatic injury to severe liver disease. The so-
called celiac hepatitis is a frequent, benign, clinically 
silent condition which resolves on a GFD. Autoimmune 
liver diseases are less common and are associated 
in the majority of cases with clinical signs and 
symptoms of chronic liver disease, which need specific 
immunosuppressive therapy, rather than just GFD. 
Although rarely, CD may be also associated with 
severe liver involvement requiring liver transplant. In 
light of this background early diagnosis and treatment 
of CD-associated chronic and severe liver diseases may 
play an important role in the prognosis of this clinical 
entities. To this end, screening for liver involvement in 
celiac children and for CD by means of tTGA and EMA 
in children with liver diseases should become routine 
practice.
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